Assessing Relay Therapeutics (RLAY) Valuation After FDA Breakthrough Therapy Designation For Zovegalisib [Yahoo! Finance]
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer [Yahoo! Finance]
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
Relay Therapeutics (NASDAQ:RLAY) was upgraded by analysts at Oppenheimer Holdings, Inc. from a "market perform" rating to an "outperform" rating.